 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] SK Bioscience announced on the 29th that it will supply a synthetic antigen-based microtron submutation (XBB.1.5) vaccine developed by Novavacs in Korea within this year.
The vaccine was approved for emergency use by the Ministry of Food and Drug Safety. It is the third time in the world to supply the XBB-based Novavax mutation improvement vaccine in the synthetic antigen platform after the United States and Europe, and the first among Asian countries. SK Bioscience has an exclusive right to supply and commercialize Novavac's COVID-19 improved vaccine.
Novavacs COVID-19 vaccine has been developed as a synthetic antigen method that has been used for a long time in flu and hepatitis B vaccines. Novavacs confirmed the immune response to XBB.1.5, XBB.16, and XBB.2.3 of the improved vaccine through nonclinical trials. It also confirmed neutralizing antibody reactions to other lower strains BA.2.86, EG.5.1, FL.1.5.1, and XBB.1.16.6, as well as CD4+ T cell responses involved in immunity of EG.5.1 and XBB1.16.6.
Earlier in October, the U.S. Food and Drug Administration (FDA) approved the emergency use of the Novavacs vaccine to inoculate people aged 12 or older. The European Medicines Agency (EMA) has also officially approved the vaccine, and the World Health Organization (WHO) has recently put it on its emergency list.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
